Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 4/20 | 0.40 |
| ▸ | RARA | P10276 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | RARG | P13631 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 3/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365986 | 0.85 | OPRD1 (0.40) | PDK2CNR2PTGS2RAB9ASMN1; SMN2 | |
| SCHEMBL26393071 | 0.82 | PKM (0.33) | PDK2RARARARBRARGNPC1 | |
| SCHEMBL12366097 | 0.81 | PDK2 (0.41) | PDK2CNR2PTGS2RAB9ASMN1; SMN2 | |
| SCHEMBL16381648 | 0.81 | KDM4E (0.40) | RARARARBRARGPTGS2KDM4E | |
| SCHEMBL8771676 | 0.81 | PDK2 (0.47) | PDK2CNR2PTGS2SMN1; SMN2POLB | |
| SCHEMBL2682796 | 0.80 | HIF1A (0.35) | — | |
| SCHEMBL12365968 | 0.79 | PDK2 (0.38) | PDK2PTGS2RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12365970 | 0.79 | PDK2 (0.38) | PDK2PTGS2RAB9ASMN1; SMN2MAPT | |
| SCHEMBL12390207 | 0.79 | PDK2 (0.38) | PDK2PTGS2RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6590616 | 0.78 | CYP3A4 (0.35) | PDK2RARARARBRARGRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PDK2 3920/4885RARA 3177/4885RARB 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.